158 related articles for article (PubMed ID: 22151967)
1. Oral administration of interferon-α2b-transformed Bifidobacterium longum protects BALB/c mice against coxsackievirus B3-induced myocarditis.
Yu Z; Huang Z; Shao C; Huang Y; Zhang F; Yang J; Deng L; Zeng Z; Deng Q; Zeng W
Virol J; 2011 Dec; 8():525. PubMed ID: 22151967
[TBL] [Abstract][Full Text] [Related]
2. Bifidobacterium as an oral delivery carrier of interleukin-12 for the treatment of Coxsackie virus B3-induced myocarditis in the Balb/c mice.
Yu Z; Huang Z; Sao C; Huang Y; Zhang F; Yang J; Lian J; Zeng Z; Luo W; Zeng W; Deng Q
Int Immunopharmacol; 2012 Jan; 12(1):125-30. PubMed ID: 22088614
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone IIA Ameliorate Coxsackie Virus B3-Induced Viral Myocarditis through the Inhibition of Inflammation and Modulation T Helper 1/T Helper 2 Balance in Mice.
Guo G; Zhao Q; Wang Q; Li E
Pharmacology; 2019; 103(3-4):136-142. PubMed ID: 30602153
[TBL] [Abstract][Full Text] [Related]
4. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis.
Padalko E; Nuyens D; De Palma A; Verbeken E; Aerts JL; De Clercq E; Carmeliet P; Neyts J
Antimicrob Agents Chemother; 2004 Jan; 48(1):267-74. PubMed ID: 14693549
[TBL] [Abstract][Full Text] [Related]
5. Increased mRNA expression of interferon-induced Mx1 and immunomodulation following oral administration of IFN-alpha2b-transformed B. longum to mice.
Yu Z; Zeng Z; Huang Z; Lian J; Yang J; Deng Q; Zeng W
Arch Microbiol; 2010 Aug; 192(8):633-8. PubMed ID: 20535450
[TBL] [Abstract][Full Text] [Related]
6. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
Henke A; Jarasch N; Martin U; Wegert J; Wildner A; Zell R; Wutzler P
Int J Med Microbiol; 2008 Jan; 298(1-2):127-34. PubMed ID: 17897883
[TBL] [Abstract][Full Text] [Related]
7. α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis.
Wu CY; Feng Y; Qian GC; Wu JH; Luo J; Wang Y; Chen GJ; Guo XK; Wang ZJ
Clin Exp Immunol; 2010 Oct; 162(1):178-87. PubMed ID: 20726989
[TBL] [Abstract][Full Text] [Related]
8. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.
Henke A; Zell R; Ehrlich G; Stelzner A
J Virol; 2001 Sep; 75(17):8187-94. PubMed ID: 11483764
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of losartan in mice with chronic viral myocarditis induced by coxsackievirus B3.
Zhang YY; Li JN; Xia HH; Zhang SL; Zhong J; Wu YY; Miao SK; Zhou LM
Life Sci; 2013 Jul; 92(24-26):1186-94. PubMed ID: 23702425
[TBL] [Abstract][Full Text] [Related]
10. Remission of CVB3-induced viral myocarditis by in vivo Th2 polarization via hydrodynamics-based interleukin-4 gene transfer.
Jiang Z; Xu W; Li K; Yue Y; Xu L; Ye F; Xiong S
J Gene Med; 2008 Aug; 10(8):918-29. PubMed ID: 18512734
[TBL] [Abstract][Full Text] [Related]
11. Bifidobacterium as an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice.
Long RT; Zeng WS; Chen LY; Guo J; Lin YZ; Huang QS; Luo SQ
Int J Obes (Lond); 2010 Apr; 34(4):712-9. PubMed ID: 20065960
[TBL] [Abstract][Full Text] [Related]
12. Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis.
Li M; Yan K; Wei L; Yang J; Lu C; Xiong F; Zheng C; Xu W
Antiviral Res; 2015 Nov; 123():50-61. PubMed ID: 26343012
[TBL] [Abstract][Full Text] [Related]
13. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis.
Fan X; Yue Y; Xiong S
Antiviral Res; 2017 Apr; 140():121-132. PubMed ID: 28137624
[TBL] [Abstract][Full Text] [Related]
14. Blocking the CD40-CD40L interaction by CD40-Ig reduces disease progress in murine myocarditis induced by CVB3.
Bo H; Zhenhu L; Lijian Z
Cardiovasc Pathol; 2010; 19(6):371-6. PubMed ID: 19914091
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis.
Zhang L; Parham NJ; Zhang F; Aasa-Chapman M; Gould EA; Zhang H
Vaccine; 2012 Mar; 30(13):2301-8. PubMed ID: 22306858
[TBL] [Abstract][Full Text] [Related]
16. Ameliorating effect of IFN-beta and anti-IFN-beta on coxsackievirus B3-induced myocarditis in mice.
Lutton CW; Gauntt CJ
J Interferon Res; 1985; 5(1):137-46. PubMed ID: 2985716
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the protective capability of a recombinant coxsackievirus B3 variant expressing interferon-gamma.
Henke A; Jarasch N; Martin U; Zell R; Wutzler P
Viral Immunol; 2008 Mar; 21(1):38-48. PubMed ID: 18355121
[TBL] [Abstract][Full Text] [Related]
18. IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-gamma and macrophage and neutrophil populations in the heart.
Fairweather D; Frisancho-Kiss S; Yusung SA; Barrett MA; Davis SE; Steele RA; Gatewood SJ; Rose NR
J Immunol; 2005 Jan; 174(1):261-9. PubMed ID: 15611248
[TBL] [Abstract][Full Text] [Related]
19. Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.
Henke A; Jarasch N; Wutzler P
Expert Rev Vaccines; 2008 Dec; 7(10):1557-67. PubMed ID: 19053211
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in coxsackievirus B3-induced myocarditis: IL-12Rbeta1 signaling and IFN-gamma increase inflammation in males independent from STAT4.
Frisancho-Kiss S; Nyland JF; Davis SE; Frisancho JA; Barrett MA; Rose NR; Fairweather D
Brain Res; 2006 Dec; 1126(1):139-47. PubMed ID: 16949558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
